# Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

> **NCT06071013** · PHASE1,PHASE2 · RECRUITING · sponsor: **China Medical University Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- EGFR Gene Mutation
- EGFR-TKI Resistant Mutation

## Interventions

- **DRUG:** Nintedanib, gefitinib, erlotinib, afatinib, osimertinib

## Key facts

- **NCT ID:** NCT06071013
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2026-08-27
- **Final completion:** 2026-08-27
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06071013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06071013, "Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06071013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*